Floatz logo

DISOMOTIDE

Recurrent Melanoma

National Cancer Institute (NCI)protein_peptidePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

450 Active assets in the Recurrent Melanoma cohort.

Asset / SponsorPhaseRating
Gm-Csf
Ultimovacs ASA
Phase 4BBB
Cediranib
M.D. Anderson Cancer Center
Phase 3BBB
Sargramostim
Mayo Clinic
Phase 3BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
DACARBAZINE
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

DISOMOTIDE is also rated in:

cutaneous melanomaDormant
B
Indicative ·
61 / 100
View asset →
uveal melanomaDormant
B
Indicative ·
57 / 100
View asset →
metastatic melanomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →